353 related articles for article (PubMed ID: 12946050)
1. What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?
Youdim MB
J Neural Transm Suppl; 2003; (65):73-88. PubMed ID: 12946050
[TBL] [Abstract][Full Text] [Related]
2. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
Mandel S; Maor G; Youdim MB
J Mol Neurosci; 2004; 24(3):401-16. PubMed ID: 15655262
[TBL] [Abstract][Full Text] [Related]
3. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S
J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524
[TBL] [Abstract][Full Text] [Related]
4. The mouse MPTP model: gene expression changes in dopaminergic neurons.
Kühn K; Wellen J; Link N; Maskri L; Lübbert H; Stichel CC
Eur J Neurosci; 2003 Jan; 17(1):1-12. PubMed ID: 12534964
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
Dong Z; Ferger B; Feldon J; Büeler H
J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
[TBL] [Abstract][Full Text] [Related]
6. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.
Finkelstein DI; Billings JL; Adlard PA; Ayton S; Sedjahtera A; Masters CL; Wilkins S; Shackleford DM; Charman SA; Bal W; Zawisza IA; Kurowska E; Gundlach AL; Ma S; Bush AI; Hare DJ; Doble PA; Crawford S; Gautier EC; Parsons J; Huggins P; Barnham KJ; Cherny RA
Acta Neuropathol Commun; 2017 Jun; 5(1):53. PubMed ID: 28659169
[TBL] [Abstract][Full Text] [Related]
7. Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
Heng Y; Zhang QS; Mu Z; Hu JF; Yuan YH; Chen NH
Toxicol Lett; 2016 Jan; 243():7-21. PubMed ID: 26723869
[TBL] [Abstract][Full Text] [Related]
8. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.
Weinreb O; Mandel S; Youdim MBH; Amit T
Free Radic Biol Med; 2013 Sep; 62():52-64. PubMed ID: 23376471
[TBL] [Abstract][Full Text] [Related]
9. Cell senescence induced by toxic interaction between α-synuclein and iron precedes nigral dopaminergic neuron loss in a mouse model of Parkinson's disease.
Shen QQ; Jv XH; Ma XZ; Li C; Liu L; Jia WT; Qu L; Chen LL; Xie JX
Acta Pharmacol Sin; 2024 Feb; 45(2):268-281. PubMed ID: 37674042
[TBL] [Abstract][Full Text] [Related]
10. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
11. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease.
Mandel S; Grünblatt E; Youdim M
J Neural Transm Suppl; 2000; (60):117-24. PubMed ID: 11205134
[TBL] [Abstract][Full Text] [Related]
12. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.
Robertson DC; Schmidt O; Ninkina N; Jones PA; Sharkey J; Buchman VL
J Neurochem; 2004 Jun; 89(5):1126-36. PubMed ID: 15147505
[TBL] [Abstract][Full Text] [Related]
13. Apelin-13 protects dopaminergic neurons in MPTP-induced Parkinson's disease model mice through inhibiting endoplasmic reticulum stress and promoting autophagy.
Zhu J; Dou S; Jiang Y; Chen J; Wang C; Cheng B
Brain Res; 2019 Jul; 1715():203-212. PubMed ID: 30914252
[TBL] [Abstract][Full Text] [Related]
14. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Youdim MB; Stephenson G; Ben Shachar D
Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
[TBL] [Abstract][Full Text] [Related]
15. The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice.
Youdim MB; Grünblatt E; Mandel S
J Neural Transm (Vienna); 2007 Feb; 114(2):205-9. PubMed ID: 16736232
[TBL] [Abstract][Full Text] [Related]
16. Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.
Wang QM; Xu YY; Liu S; Ma ZG
Oncotarget; 2017 Jul; 8(29):47284-47295. PubMed ID: 28521299
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
18. Apelin-36 mitigates MPTP/MPP
Zhu J; Dou S; Wang C; Jiang Y; Wang C; Cheng B
Brain Res; 2019 Oct; 1721():146334. PubMed ID: 31306618
[TBL] [Abstract][Full Text] [Related]
19. Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Schlüter OM; Fornai F; Alessandrí MG; Takamori S; Geppert M; Jahn R; Südhof TC
Neuroscience; 2003; 118(4):985-1002. PubMed ID: 12732244
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP.
Grünblatt E; Mandel S; Youdim MB
Ann N Y Acad Sci; 2000; 899():262-73. PubMed ID: 10863545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
